Introduction
If you work with peptides in any capacity, research, compounding, supply, or clinical development, you've likely noticed that the testing environment is changing fast. At ACS Peptide Testing Labs, we process hundreds of samples monthly, giving us a unique window into what the market actually needs. Here's what the data tells us about peptide testing in 2026.
Testing Volume by Peptide Category
Our 2025-2026 data reveals clear patterns in which peptides generate the most testing demand:
| Peptide Category | Share of Testing Volume | YoY Growth |
|---|---|---|
| GLP-1 Agonists (semaglutide, tirzepatide) | 31% | +85% |
| Tissue-Repair Peptides (BPC-157, TB-500) | 18% | +22% |
| Metabolic/Research (SS-31, MOTS-c) | 12% | +45% |
| Multi-Agonists (retatrutide) | 9% | +210% |
| Cosmetic Blends (GHK-Cu combinations) | 7% | +38% |
| Growth Hormone Secretagogues | 6% | +5% |
| Other Research Peptides | 17% | +15% |
Which Tests Are Most Requested?
HPLC Purity Testing
Still the #1 requested test, accounting for about 65% of all orders. Researchers and pharmacies need to confirm that the peptide they purchased actually meets purity specifications. Our HPLC purity testing guide covers what this test reveals.
Key trend: More clients are requesting gradient method optimization for complex peptides like tirzepatide, which has a lipidated fatty acid chain that requires specialized HPLC conditions.
Mass Spectrometry Identity Confirmation
Identity testing has grown from 30% to 48% of orders over the past 18 months. The driver is simple: our COA accuracy study showed that approximately 8% of tested samples contained the wrong peptide entirely.
For compounding pharmacies, identity confirmation isn't optional, it's a regulatory requirement for incoming API verification.
Contaminant Screening
Demand for heavy metal and residual solvent testing has nearly doubled since 2024. This reflects:
- FDA emphasis on contaminant testing for compounded injectables
- Researcher awareness that metal contaminants can confound cell culture results
- New clients from the pharmaceutical quality space entering the research peptide market
Quantity/Net Content Testing
Net content testing is an emerging category. Pharmacies and researchers want to know: does this 5 mg vial actually contain 5 mg? Our data shows that approximately 22% of vials tested fall outside ±10% of the labeled amount.
Client Segments Driving Demand
Compounding Pharmacies: The Fastest-Growing Segment
503A and 503B pharmacies now represent approximately 35% of our client base, up from 15% in 2024. The growth drivers:
- FDA enforcement actions requiring quality documentation
- State pharmacy board audits requesting third-party COAs
- Patient safety concerns driving voluntary testing programs
These clients typically order comprehensive panels: purity + identity + endotoxin + quantity.
Research Institutions
Academic and biotech researchers remain our largest segment by client count, though pharmacy clients submit more samples per order. Trends include:
- Grant requirements increasingly mandate independent testing
- Reproducibility concerns drive verification of key reagents
- Multi-site studies need standardized peptide quality data
Peptide Suppliers
Forward-thinking suppliers use independent testing as a competitive differentiator. We've seen a shift from suppliers testing only when customers complain to proactive batch-release testing programs.
